Payment overview · 2025
General Payments
$1,656.91
72 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Morache, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SAN DIEGO, CA · NPI 1689621567
Verified facts
What the public records show
CMS Open Payments records show Christopher Morache, MD received $1,656.91 in general payments during 2025 across 72 reported records.
Neurocrine BioSciences, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Ingrezza, Invega Sustenna, Lybalvi, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $403.74 | 24.4% | 12 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $256.01 | 15.4% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.79 | 9.6% | 9 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.42 | 9.2% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.04 | 9.0% | 10 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $111.80 | 6.8% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $83.00 | 5.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.77 | 4.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.02 | 4.2% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $62.52 | 3.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.08 | 2.9% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $27.92 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.21 | 1.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.59 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,656.91 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $403.74 | 12 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $256.01 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $167.83 | 10 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $152.42 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $122.84 | 7 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $83.00 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $83.00 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $81.77 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $71.79 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.02 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $62.52 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.08 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $40.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $8.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Aripiprazole | Aripiprazole | 147 | 38 |
| Trazodone Hcl | Trazodone Hcl | 142 | 31 |
| Clonazepam | Clonazepam | 126 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 21 |
| Clozapine | Clozapine | 114 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 19 |
| Olanzapine | Olanzapine | 98 | 20 |
| Alprazolam | Alprazolam | 90 | 19 |
| Bupropion Xl | Bupropion Hcl | 83 | 14 |
| Gabapentin | Gabapentin | 76 | 18 |
| Mirtazapine | Mirtazapine | 70 | 16 |
| Lorazepam | Lorazepam | 69 | 18 |
| Protriptyline Hcl | Protriptyline Hcl | 68 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 12 |
| Lithium Carbonate | Lithium Carbonate | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 55 | 13 |
| Ingrezza | Valbenazine Tosylate | 55 | suppressed |
| Lamotrigine | Lamotrigine | 53 | 17 |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Vraylar | Cariprazine Hcl | 40 | suppressed |
| Armodafinil | Armodafinil | 39 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 38 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 34 | suppressed |
| Belsomra | Suvorexant | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Ramelteon | Ramelteon | 29 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Nefazodone Hcl | Nefazodone Hcl | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Zaleplon | Zaleplon | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Azstarys | Serdexmethylphen/Dexmethylphen | 18 | suppressed |
| Loxapine | Loxapine Succinate | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 15 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Metformin Hcl | Metformin Hcl | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Risperidone Er | Risperidone Microspheres | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Flurbiprofen | Flurbiprofen | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Nuvigil | Armodafinil | 12 | suppressed |
| Tranylcypromine Sulfate | Tranylcypromine Sulfate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,656.91 · 72 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ARISTADA, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, LOREEV XR, LYBALVI, QULIPTA, Qelbree, REXULTI, SPRAVATO, SUBLOCADE, UBRELVY, VRAYLAR, ZURZUVAE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error